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ABSTRACT
All biomaterials used in dentistry must be evaluated for biocompatibility using screening assays to protect patient health 
and safety.  The purpose of this review is to explain the international biocompatibility guidelines, and to explain the 
structure of a test program. The test program requires the structured assessment of materials into four phases; general 
toxicity, local tissue irritation, pre-clinical, and clinical evaluation.   Different types of screening assays are available, 
and it is important to understand the advantages and limitations of the various types of assays that are available, so that 
they can be selected for appropriateness and interpreted accurately.  New scientific advances in terms of the chemical 
properties of dental materials, tissue engineering, stem cell, genetic transfer, biomaterial, and growth factor therapies are 
under development.  These new therapies create improved opportunities to restore and regenerate oral tissues, but they 
can also present new hazards to patients. Prior to their clinical use, these new technologies must be proven to be safe, 
and not hazardous to human health.  A structured biocompatibility assessment and advice on the selection of assays 
are outlined to evaluate these new therapies.
Key words: Cytotoxicity, biocompatibility, dental materials, growth factors, gene therapy, tissue engineering, stem cell 
therapy.
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INTRODUCTION
The need for biocompatible materials for use in restorative 
dentistry and endodontics has generated a requirement for 
cytotoxicity assays to screen compounds and characterize 
the potentially harmful effects of a material to oral tissues 
prior to clinical use.  Cytotoxicity screening assays provide 
a measure of cell death caused by materials or their extracts. 
There are a vast number of cytotoxicity screening methods 
available for measuring the biocompatibility of  a dental 
restorative material.  The application of different methods 
of cytotoxicity screening has been shown to produce a spec-
trum of biocompatibility assessments for the same material 
(1-4). Evaluating the biocompatibility of a material using an 
in vitro cell culture assay, and from this, attempting to predict 
in vivo oral tissue responses is controversial (5).  It has been 
found that the biocompatibility assessments produced by 
cell culture assays have not necessarily been in agreement 
with animal in vivo biocompatibility implantation test (6-9). 
These interpretational difficulties have provided the impetus 
for efforts to standardize the use of cytotoxicity assays, and 
regulate the context of their application at national and 
supranational levels.   
BIOCOMPATIBILITY
The traditional concept of biocompatibility is regarded as a 
lack of significant adverse reaction between the oral tissues 
(10).  It is now recognized from that there are few materials, 
if  any, which do not create a significant interaction with the 
host tissues (11). Such reactions may aid the oral healing 
response following restorative treatment.  An updated defini-
tion of biocompatibility might be the ability of a restorative 
material to induce an appropriate and advantageous host 
response during its intended clinical usage.
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CYTOTOXICITY
Dental material biocompatibility has long been described 
throughout the dental literature, however, information about 
the factors that determine biocompatibility responses is only 
just emerging.  An obvious determinant of biocompatibility 
is the effect a material may have on cell survival.  The term 
‘cytotoxicity’ is used to describe the cascade of molecular 
events that interfere with macromolecular synthesis, causing 
unequivocal cellular and functional and structural damage 
(12).  Cytotoxicity is a difficult process to characterize as there is 
almost an infinite number of ways to trigger cellular disruption. 
An understanding of this complexity is compounded by the 
capabilities of the cellular proteins to aid or extend cell survival 
(13), and the genetic disposition of cells to activate particular 
modes of cell death (14).  Cytotoxic-mediated reactions can 
be employed therapeutically, such as in cancer chemotherapy 
(15).  However, as part of dental treatment, it is advantageous 
to maintain maximal tissue vitality and cytotoxic reactions 
must be prevented, hence the requirement to screen all dental 
compounds before they are used clinically.  
BIOCOMPATIBILITY TESTING STANDARDS
The International Organization for Standardization (ISO) 
is a worldwide federation of national standards bodies (ISO 
member bodies).  At present, national standards exist for 
biocompatibility testing methods (16-18).  International 
standards cover specifically dental materials (ISO 7405) (19) 
and medical devices (ISO 10993) (20), which also include 
dental materials.  A dental material is defined as a substance 
or combination of  substances specially prepared and/or 
presented for use by authorized persons in the practice of 
dentistry and/or its associated procedures (19).
1. International standard ISO 7405: International standard 
ISO 7405 (19) is entitled the Preclinical evaluation of bio-
compatibility of medical devices used in Dentistry - Test 
methods for Dental Materials.  This ISO document was 
prepared in conjunction with the World Dental Federation. 
It concerns the preclinical testing of materials used in Den-
tistry, and supplements ISO 10993 (20).
2. International standard ISO 10993: International standard 
ISO 10993 (20) entitled the Biological evaluation of medical 
devices is a combination and harmonization of Interna-
tional and National Standards and guidelines.  The stated 
primary goal of ISO 10993 is the protection of humans. 
This document has been continually updated, and is the 
overall guidance document for the selection of tests, to be 
used for the evaluation of biological responses relevant to 
medical or dental material and device safety.
Guidelines ISO 7405 (19) and ISO 10993 (20) and have recom-
mended standard practices for the biological evaluation of 
dental materials.  In summary these include;  (i) It is incumbent 
upon the dental material manufacturer to select the appropriate 
tests, based on the intended use of the material, and known 
and assumed toxicity profile of the material or its components. 
(ii) A manufacturer may select one of three cytotoxicity tests 
in preference to another because of cost, experience or other 
reasons.  (iii) Overall, there are four levels of testing. New 
materials should be evaluated using initial cytotoxicity and 
secondary tissue screening tests prior to extensive animal 
experimentation testing and clinical trials. (iv)The test result 
should always be evaluated and interpreted with consideration 
for the manufacturers stated use for the material.
TEST PROGRAM FOR THE BIOLOGICAL TES-
TING OF DENTAL MATERIALS
The selection and evaluation of any material or device intended 
for use in humans requires a structured assessment.  The test 
program for the biological testing of dental materials is norma-
lly divided into four stages (Table 1).  The initial tests (Phases 
I and II) are of a short duration, simple and cost effective. 
Only after completing these tests satisfactorily does a material 
progress through the testing hierarchy to become evaluated in 
preclinical animal usage studies (Phase III) prior to clinical 
testing with a limited number of patients (Phase IV).
 
CYTOTOXICITY SCREENING METHODS
General guidance for in vitro cytotoxicity testing is presen-
ted in ISO 10993-5.  Detailed test protocols for the agar 
diffusion and filter diffusion methods appropriate to dental 
materials, are included in ISO 7405.  For in vitro cytotoxi-
city screening, the recommended testing methods include; 
(i) Direct cell culture and culture extract testing, or barrier 
screening assays.  (ii) Agar diffusion testing.  (iii) Filter 
diffusion testing, and (iv) Dentin barrier testing.  These 
methods are described in the following paragraphs:
1a. Direct cell culture and culture extract testing: More than 
twenty different cell culture techniques have been applied 
to assess the cytotoxicity of dental materials (21-22).  The 
strategy has been to test the toxicity of individual compound 
components of a dental material when placed directly onto 
cells in a mono-layer culture, over a short duration (normally 
>24 hours).  Dose-response curves can then be determined 
which estimate the cytotoxic potential of compounds within 
a material.  This information is valuable to manufacturers, 
who are then able to formulate dental materials potentially 
containing the least quantity of cytotoxic compounds.  The 
practical complication of cell culture cytotoxicity screening 
is that cell and colony counts are time consuming, tedio-
us, and sensitive to minor variations in morphology.  Cell 
counts enumerate morphologically intact cells but do not 
distinguish between living and dead cells.  Colony counts 
often require subjective judgments about what constitutes 
a colony, and are subject to a wide variety of troublesome 
artifacts that can greatly complicate their interpretation. 
1b. Barrier testing methods: Of the four recommended cyto-
toxicity tests (ISO 7405) (19), three are examples of barrier 
testing methods.  One of the criticisms of cell culture tests 
with direct material-cell contact is that the testing situation 
is often not clinically relevant, as most materials used to 
restore lost tooth substance are not in direct contact with 
the cells.  There is normally a barrier of dentin between the 
material and the pulp tissue (7).  Barrier testing methods 
are used to mimic the dentin barrier, to test for the ability 
of a material to dissolve dentin and diffuse through den-
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tinal tubules, thereby permitting an estimate of material 
toxicity related to its diffusional capacity.  The ability of 
this simple strategy to determine the cytotoxic hazard of a 
material in vitro and generalize this to in vivo systems has 
been somewhat successful, mainly because the results are 
relatively easy to interpret.  This explains the adoption of 
barrier testing, as the method recommended for the bulk 
of cytotoxicity screening assays for dental materials (ISO 
10993-5) (20).
2. Agar diffusion test: Probably the longest established cyto-
toxicity barrier testing method is the Agar Diffusion Test 
or the Tissue Culture Overlay Test (23,24) where the test 
material is simply incubated on a layer of agar overlying a 
monolayer cell culture.  This method is used for testing the 
non-specific cytotoxicity of the leachable components of 
test substances after diffusion through agar or agarose (ISO 
7405) (19) using permanent cell lines.  These cells are stained 
with neutral red vital stain dye, overlaid with an agar layer 
on which the test material is incubated for 24 hours (25). 
The presence of leachable toxic substance(s) is manifested 
by the loss of dye within the cells as they lyse (a type of 
membrane integrity assay) provided the concentration and 
cytotoxicity of the diffusing substance(s) are high enough. 
Although simple and inexpensive to use as a cytotoxicity 
screening method, this technique has the disadvantage that 
materials or compounds have to diffuse through the agar 
overlaying the monolayer of cells.  Therefore, materials that 
do not dissolve in or diffuse through agar will not cause ce-
llular damage, although they could nevertheless be cytotoxic 
when employed clinically.  
3. Filter diffusion testing methods: The Millipore (cellulose 
acetate) filter method modifies the oral contact situation 
in that primary cells are grown on one side of the filter, 
and the test material is placed in contact with the opposite 
surface of the filter.  Thus, any leachable substance must 
diffuse through the 0.45µm filter pores to exert any cytotoxic 
effects on the cells (26).  The appearance of the test filters 
at the material cell contact areas is registered according to 
a scoring system to classify the cytotoxic response to a test 
material (ISO 7405) (19).  Assay endpoints which have been 
used with this testing method include lactate dehydrogena-
se, glucose-6-phosphate dehydrogenase and cytochrome 
oxidase (examples of metabolic impairment assays).  No 
differences in enzyme activity patterns have been observed 
among the enzymes tested (7), indicating that the results 
from all of these endpoints are comparable.  
4. Dentin barrier testing: Although recommended as cyto-
toxic screening methods (ISO 7405) (19) the agar overlay 
test and the filter diffusion test, may not necessarily be the 
best methods, for mimicking barriers of the oral environ-
ment.  A recent adjunct to the cytotoxicity tests has been 
the development of  dentin barrier testing, or the model 
cavity method as it is sometimes known (27).  The original 
idea by Outhwaite et al., (28) has been refined over the 
years to define the factors which affect diffusion through 
dentinal tubules.  These include the size and concentration 
of molecules, density of dentinal tubules, length of dentinal 
tubules, diameter of tubules, the effect of temperature, and 
measurement of cytotoxic effects on pulpal cells (29-31). 
Clearly, adopting the use of a dentin barrier simulates the 
in vivo oral environment more closely, thereby helping to 
identify specific dental compound components which may 
be responsible for pulpal effects through dentin, an option 
not available with other testing methods.  The dentin ba-
rrier test may also help identify compounds that repress or 
intensify the cytotoxic effect of a substance, by reducing or 
increasing dentin permeability (32-35).  With the importance 
of the principle of generalizing in vitro cytotoxicity findings 
to the human in vivo clinical situation, this technique is 
recommended for use in preference to the others  (ISO 
7405) (19).  
ENDPOINTS OF THE CYTOTOXICITY ASSAY
The recommended testing methods (ISO 10993; ISO 7405) 
use cell counting, dye-binding, metabolic impairment or 
membrane integrity as end-points of the cytotoxicity test 
or assay.  The direct use of cell and colony counting as an 
assay endpoint is probably the least reliable method.  Ideally, 
endpoints should conform to strict criteria for classifying 
results, so that the subjective element when determining a 
measure of cytotoxicity for a test material is minimized. 
This makes assays a very reproducible and therefore power-
ful form of cytotoxicity testing, as it permits a stable basis 
for comparing results between laboratories.  A description 
of the assay endpoints are in the following paragraphs:
1. Metabolic impairment assay: Metabolic impairment 
assays measure the decay of enzyme activity or metabolite 
concentration following toxic damage.  Cytotoxicity tes-
ting by this means has included alterations in lysosomal 
acid phosphatase (24), cytoplasmic lactate dehydrogenase 
(36,37), succinate dehydrogenase (38), enzyme activity (39), 
and the incorporation of labelled precursors (40).  These 
methods are generally more complex and artifact-prone than 
membrane integrity assays.  Their validity requires that very 
precise conditions be met; deviation from these conditions 
can lead to extremely serious errors that invalidate the assay. 
Metabolic impairment assays are nevertheless popular be-
cause they distinguish between normal and reduced levels of 
cellular metabolism, which is a surrogate index of metabolic 
viability though not necessarily an accurate predictor of 
cellular proliferative capability.  The end point assumption 
is that the proliferative capability, and metabolic activity of 
viable cells are preserved. 
2. Membrane integrity assay: Membrane integrity assays 
measure the ability of  cells to exclude impermeable ex-
tracellular molecules.  They can be either colorimetric or 
fluorescent, and require the same instrumentation as dye-
binding assays.  Assays of this type tend to be less artifact 
prone than metabolic impairment assays, but have the same 
ability to estimate ‘viability’, which in this case is the ability 
to distinguish between the normal and impaired exclusion 
of extracellular molecules.  Membrane integrity assays are 
complicated by the fact that living cells slowly accumulate 
probe molecules, therefore, their protocols must be carefu-
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lly optimized.  Trypan blue staining (41), red vital staining 
(25), and neutral red staining combined with amido black 
staining (42), have all been used to study the toxicity of 
some endodontic materials for the routine determination 
of cell viability.  Stanford (25) recommends staining cells 
with neutral red vital stain dye, overlaid with an agar layer 
on which the test material is incubated for 24 hours.  After 
incubation, the presence of leach-able toxic substance(s) is 
manifested by the loss of dye within the cells as the mem-
branes lyse.  Alternatively, some dyes or isotopes are used 
which are only taken up by viable cells, diacetyl fluorescein 
(43), or the Radiochromium (51Cr) Assay (44,45). The use 
of this assay, allows direct cell-material contact, in dissolved 
materials as well as semisolid, setting or set materials (25). 
In general this assay is restricted to measuring membrane 
permeability, one of the final events of cell death; sub-lethal 
cellular changes are not measured. This technique has been 
shown to give similar biocompatibility results to the agar 
overlay method of cytotoxicity screening (46,47), with the 
agar overlay method being less expensive and without the 
complications of radioisotope handling and disposal.  Des-
pite improvements in the utilization of the screening assays, 
surprisingly little attention has been paid to the fact that the 
toxicity parameters selected for these screening tests should 
be appropriate to the chemical nature of the components 
within the test materials.  For example, hydrophilic chemicals 
are likely to change intracellular enzyme activities at lower 
concentrations rather than influencing membrane per-
meability.  Therefore, a metabolic impairment assay would 
seem to be the most appropriate test method, rather than a 
membrane integrity assay.  This situation would be reversed 
for a test material containing lipophillic chemicals.  All this 
evidence suggests that in vitro biocompatibility assays can 
only provide accurate information about test materials if  
they are used appropriately.
ANIMAL USAGE ASSAY
Biological testing relies heavily on animal experimentation. 
Before a dental material can be used clinically, it must always 
be tested to the fullest extent in several species of laboratory 
animals to establish its systemic and cytotoxic properties 
(48).  The use of animals helps to predict the possible toxic 
hazards that may be encountered in man. However, there are 
some notorious exceptions such as thalidomide when this 
did not happen (49).  Sometimes dogs (50) and ferrets (51) 
among other large animals, are used to evaluate the biologi-
cal responses of teeth to experimental restorative treatments. 
The ISO 7405 guidelines recommend preclinical testing in 
adult non-human primates (19). Every year it is estimated 
that 57,000 non-human primates are used worldwide for 
medical experimentation, as well as many types of animals 
including millions of rodents (48).  The precise numbers 
of animals used for dental material testing are not known, 
but they must only be a small fraction of the total numbers. 
The dental materials to be evaluated should be placed using 
routine restoration techniques, to closely mimic the intended 
clinical usage of the test materials.  Traditional restorative 
materials such as zinc oxide eugenol and more commonly 
calcium hydroxide are often used to restore adjacent teeth at 
the same time.  These traditional restorative materials have 
a long-established record of clinical success, and are used 
for comparison with the test materials.  The teeth restored 
with calcium hydroxide are also used as ‘control teeth,’ to 
ensure that the pulpal reactions to restorative treatment are 
representative with previous investigations.   The ISO 7405 
guidelines recommend that 7 +/-2 days (short-term) and 70 
-/+ 5 days (long-term) have elapsed before the restored teeth 
are carefully extracted after the administration of general 
anesthetic and venous infiltration perfusion.  However, 
many investigations prefer to show a timed sequence of 
reactions to test restorative materials and sometimes, 3, 7, 
14 30 and 60 day time-periods are used (52,53).  Short-time 
periods are often used because non-human primate usage 
testing are expensive investigations to complete.  However, 
the use of short-term studies may not show the full healing 
and regenerative response of teeth to test materials.  Some 
other investigators prefer longer post-treatment time-pe-
riods of between 30 and 730 days (54,55).  Increasing the 
length of  the post-treatment extraction period increases 
the probability of detecting healing problems and compli-
cations associated with test materials.  Some direct pulp 
capped teeth appear to be healing early on but can become 
non-vital several weeks later (56).  Another prime example 
is the leakage of bacteria through restorations.  Bacterial 
leakage is more commonly detected in the longer-term 
studies (54,55), but not the shorter-term studies (52,53). 
Bacteria are detected using Brown and Brenn (57) or other 
histological stains for gram positive microorganisms (58). 
The presence of bacteria is often a more serious cause of 
pulpitis and necrosis, than the test-materials in isolation 
(59,60).  Whatever the advantages and limitations of selec-
ting different testing time-periods, adhering to the 70 -/+ 5 
days time-period with some teeth is important in order to 
accomplish some commonality and comparability between 
all the different investigations.
Histological processing and analysis of pulp reactions: Fo-
llowing extraction, the restored teeth are fixed in formalin, 
dehydrated in alcohol, and demineralized in acid.  Teeth 
are then embedded in paraffin wax or plastic blocks to be 
sectioned into 5-7 micron thickness sections.  The tooth 
sections are collected on glass-slides and stained with 
hematoxylin and eosin or other stains, and processed for 
routine light microscopy histological analysis. Pulpal injury 
and regeneration is measured and categorized according 
to standardized ISO histological criteria (19).  The infla-
mmatory cell activity of  each pulp is categorized from 
“none,” “slight,” and “moderate” to “severe”, according to 
published criteria (61).  The categories of pulp inflammation 
are:  none: the pulp contains few inflammatory cells, or an 
absence of inflammatory cells associated with cut tubules 
of the cavity floor; slight: the pulp has localized inflam-
matory cell lesions predominated by polymorphonuclear 
leukocytes or mononuclear lymphocytes; moderate: the 
pulp has polymorphonuclear leukocytes lesions involving 
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less than one third of  the coronal pulp; and severe: the 
pulp has polymorphonuclear leukocytes lesions involving 
less than one third of the coronal pulp.  Pulp necrosis fo-
llowing chronic inflammatory cell injury is also noted.  It is 
extremely important to separate the responses of restored 
teeth to the test materials and all the restorative variables. 
This involves taking into account whether the material is 
placed in contact with the exposed pulp, or measuring the 
cavity remaining dentin thickness (CRDT).  Few materials 
can stimulate pulp reactions if  the RDT is more than 2mm, 
therefore, the CRDT ideally should be standardized between 
all the restored teeth to 1 mm (62).  As mentioned previously, 
it is important to quantify the presence and penetration 
of bacteria leakage, to exclude and isolate this effect from 
pulpal responses to the test restorative materials.  While 
ISO criteria is standardized for pulp inflammatory activity 
and pulp necrosis; The test materials can stimulate none or 
slight categories, but must not stimulate moderate or severe 
categories of inflammation, or pulpal necrosis in order to 
pass this phase of preclinical testing (19,20).  However, there 
are no precisely defined quantitative criteria for measuring 
the reactionary and reparative healing responses (63,64). 
Such as the numbers of pulpal cell survival or dentin re-
generation (65).  These measures are left to the discretion 
of individual investigators, but comparisons between the 
traditional ‘control’ materials and the test materials are 
recommended (19).  Surprisingly, it is not necessary to eva-
luate the histological reactions of clinically restored teeth 
to meet ISO guidelines.
 
CLINICAL TESTING
The ideal approach for biocompatibility evaluation is to 
test solely in vivo with human subjects, which is problema-
tic because of legal and ethical considerations.  To protect 
human health, clinical testing can only be conducted with 
test materials and treatments that have successfully passed 
the first three phases of  biocompatibility testing recom-
mended by ISO guidelines (19,20) (Table 1).  The clinical 
testing of restorative materials are evaluated according to 
the United States Public Health Service (USPHS) (66) or 
Ryge criteria (67) prior to commercial sales.  This criteria 
requires the placement of test materials in patients following 
institutional review board approval, and patient informed 
consent. The restorations must be monitored for at least 
one year, and a 90% success rate must be achieved.  If  90% 
of the restorations are not successful over this time, the test 
material must be removed from sale in the United States. 
The purpose of the USPHS criteria was to standardize the 
collection and assessment of clinical data, however almost 
all studies have modified the criteria in some way making 
direct comparisons very difficult (68,69).  The USPHS cri-
teria to evaluate the success of restored teeth is shown in 
Table 2. These criteria require the use of two independent 
examiners trained to 80% reproducibility.  The system uses 
a grading system based on subjective observations of such 
parameters as restoration color, marginal adaptation, re-
current caries, anatomical form, as assessments of clinical 
performance.  For each parameter the scores range from 
Alpha (perfect), Beta (not perfect, but clinically accep-
table), Charlie (restoration requires placement) to Delta 
(failure).  These parameters are used in many studies as a 
continuum to judge longevity or failure, a strategy that may 
be inappropriate (68).  This is because often the estimated 
failure rate according to USPHS evaluations, does not 
match the surveys of restoration failure and replacement, 
for the same type of materials (69,70).  The reason for this 
disparity requires further investigation.  Particularly for the 
possible roles of restoration technical quality, patient diet, 
oral hygiene, and dental treatment monitoring, because this 
information is scarce.
ALTERNATIVES AND NEW DEVELOPMENTS 
FOR EVALUATING BIOCOMPATIBILITY
The optimization of in vitro cell culture assays: Much work 
is underway to further refine and optimize the cell culture 
based in vitro cytotoxicity screening tests currently in use. 
But in general, what a screening test does, at most, is to rank 
the test materials in regard to their cytotoxicity under the 
testing conditions in question.  In any form of in vitro cell 
culture test, the test system is so different from the clinical 
conditions of use, that few conclusions may be drawn as 
to the possible cytotoxicity of the material when used to 
clinically restore teeth.  Hence the need to develop in vitro 
cytotoxicity testing assays using models relevant to the 
clinical situation such as the culture of odontoblast cells, 
the culture of tooth slices and embryonic organ culture for 
evaluating the general toxicity of dental materials (Table 
1). These experimental testing strategies are described in 
the following paragraphs:
Primary Cell Lines: The choice of cell line for in vitro biolo-
gical tests which assess the cytotoxicity of dental materials is 
controversial, because the apparent cytotoxicity of a material, 
can be significantly affected by the cell line selected for the 
test (71). Permanent cell lines, such as transformed mouse 
fibroblasts (clone L-929) are generally available and are able 
to provide a means of good reproducibility of cytotoxicity 
testing between different laboratories (10). Nevertheless, it 
could be argued that permanent cell lines are simple replica-
ting systems, lacking the specific metabolic potential that the 
dental pulp or gingiva cells have in vivo (19,20). A primary 
cell culture of the odontoblasts or pulp fibroblasts could 
simulate the human in vivo tissue responses more faithfully 
(72-74).  Ideally, cultures of odontoblasts could be used for the 
in vitro cytotoxicity screening of dental restorative materials, 
but these cells cannot be readily grown when separated from 
their association with the dentin matrix (75,76).  Attempts 
have been made to transform primary oral explanted cells in 
culture, into permanent cell lines, but their phenotypic resem-
blance to the primary cell lines are questionable (77,78).  In the 
case of odontoblasts, these are post-mitotic cells, meanwhile 
the transformed cells can divide readily, for example.  These 
cells also express some different proteins in comparison to 
the original odontoblasts, and are derived from rodent rather 
than human teeth.  
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Table 1.  Testing protocols for dental biomaterials.
Test phase 1 Assays under evaluation, not yet recommended by guidelines 2 3 4 
Test evaluation Generaltoxicity 
Assays under evaluation, not yet 
recommended
Local tissue 



































Test type In vitro In vitro In vitro In vitro In vivo In vivo In vivo














days � 365 days 70 -/+ 5 days 
� 365 
days 
Test suitability        
Tissue irritation & 
inflammation No No No No Yes Yes Yes 
Hypersensitivity No No No No No No Yes 
Carcinogenic or 
mutagenic No No No No Yes Yes Yes 
Cytotoxicity and 
dentinal injury Yes Yes Yes Yes Yes Yes Yes 
Bacterial leakage No No No No No Yes Yes 
Genetic engineering No No No Yes No Yes Yes 
Growth factor 
therapy No No No Yes No Yes Yes 
Stem cell therapy No No No Yes No Yes Yes 
Criteria Assessment 
Success (Alpha) Restoration is clinically acceptable  
Secondary caries Caries lesion is visible adjacent to existing restoration 
Bulk fracture Isthmus fracture or any fracture through the main part of the restoration 
Marginal fracture Restorations appearing well adapted to tooth tissues, but with marginal 
fractures or defective margins with no evidence of caries. 
Tooth fracture The fracture of a tooth adjacent to a restoration, such as fracture of a 
cusp or small enamel fractures. 
Poor anatomic 
form
Loss of substance due to material degradation and wear, sufficient to 
result in loss of restoration form and possibly function. 
Allergic sensitivity Any kind of pain/ sensitivity requiring restoration replacement is listed 
under this category. 
Loss of tooth The tooth was lost. 
Other failure The restoration has been wholly or partially lost 
Table 2.  Modified United States Public Health Service Rating System.
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In common with other relatively differentiated cell lines, 
pulp fibroblasts can be quite readily cultured, but their 
growth characteristics and sensitivity to cytotoxins can vary 
greatly from culture to culture (79-81).  Regardless of the 
fact that permanent cell lines have an improbable relevance 
to the clinical situation.  The philosophy of guideline ISO 
10993 on the standardization of cell culture experiments is 
to advocate the use of permanent cell lines, over primary 
cell lines, to achieve a good reproducibility in the standard 
assays as part of biocompatibility screening. 
Tooth slice culture assay: The in vitro tooth culture of tee-
th maintains pulp tissue vitality and allows experimental 
conditions to be precisely controlled.  The use of cultured 
slices of teeth for some experiments preserves a close link 
to the clinical situation without the need for animal or hu-
man experimentation. This testing method was developed 
in response to ISO 7405 (19) guidelines that recommended 
alternative non-patient/non-animal testing strategies be 
evaluated. The benefit of using the tooth slice culture assay 
is that it permits the cytotoxicity screening of test materials 
on pulpal tissues (82), allows the evaluation of restorative 
therapies (83), and growth factor (84,85), and probably stem 
cell and gene therapy (Table 1), without presenting a risk 
to animal or human health (86).  Another advantage is the 
reproducibility of this method, this is because the teeth are 
maintained in identical experimental conditions and are not 
subject to animal or patient confounding variables, such 
as oral hygiene standards, treatment history and diet. The 
culture of tooth slices also provides an economical appro-
ach for investigating a high number of potential treatments 
using a near physiological and pathologically identical tooth 
population. The preservation of tooth structure allows the 
role of cavity preparation and restoration variables to be 
measured (83); until recently the effects of these variables 
was only able to be measured in animals and human clinical 
trials.  Therefore, the increased utilization of tooth slices 
as part of biocompatibility screening assays may be useful 
for reducing the numbers of  animal and clinical experi-
mentation because it can reduce the number of variables 
to be measured in the latter phases of testing.  This assay 
method requires further development, and may be useful for 
evaluating the early stages of genetic engineering, growth 
factor, and stem cell therapy (Table 1).  
The standards for evaluating the biocompatibility, cyto-
toxicity and clinical success of  restorative materials are 
continually updated or modified, according to new scientific 
advances or to prevent the recurrence of problems that have 
arisen in the past.  While there is often a strong impetus to 
periodically modify the criteria.  The need to preserve a com-
parison with previous investigations provides an incentive 
to preserve the status quo.   However, in the last update, the 
ISO 7405 guidelines recommended the evaluation of alter-
native non-patient/non-animal testing strategies.  This was 
in response to political and public pressure to reduce animal 
usage testing.  Some European countries are considering 
the introduction of legislation to ban animal usage assays 
(48).  However, it must be recognized that not all types of 
preclinical testing can be simulated or replaced by other 
means, such as in vitro modeling.  Examples of the type of 
investigations that cannot be replaced by in vitro assays are 
essentially investigations of whole body systemic effects, 
such as inflammation and carcinogenicity, or where the in-
tegrity of the blood and nerve supply is required.  Thus for 
the foreseeable future, the continued application of animal 
biocompatibility experiments is a vital safeguard to minimi-
ze possible hazards to human health.  Animal usage assays 
are the only testing methods, apart from clinical testing, that 
are suitable for evaluating tissue irritation/inflammation, 
hypersensitivity, carcinogenic or mutagenic potentials and 
bacterial leakage (Table 1).  However, there is a continuing 
requirement to develop alternative in vitro biological testing 




This review has concluded that animal and clinical scree-
ning are necessary to protect patients from possible hazards 
presented by dental materials and new biological restorative 
treatments.  This is because there are few realistic models to 
replace these forms of biocompatibility screening.  However, 
the numbers of animal and clinical screening tests can be mi-
nimized in order to make this form of testing more legally and 
ethically acceptable.  This can be achieved by not duplicating 
previous experimentation, and by the more rigorous screening 
of materials and restorative treatments using existing and ex-
perimental screening assays. The continued utilization of some 
basic cytotoxicity screening assays is questionable because of 
a limited usefulness to the structure of teeth. This problem is 
most acute for evaluating the safety of genetic engineering, 
growth factors and stem cell therapies, where some initial bio-
compatibility tests are required that allow these therapies to be 
evaluated without the need for a complete and total reliance 
on in vitro animal or clinical testing.
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